General Hospital Medicine   

Would you be comfortable with the use of DOACs?

In other words, are there benefits to identifying URI pathogens that do not necessarily have targeted therapies (e.g., rhinovirus, non-COVID-19 Corona...

Would the management change if there were complications with optic neuritis?

Do you prefer heparin, enoxaparin, DOAC, or aspirin?

How would you decide on the duration of antibiotics in this case?

Do you use prophylaxis universally or based on risk scores?

For example, should we still be targeting K>4 and Mg>2?

Should we consider this as a unique point during goal of care discussions, separate from code status, comfort measures only, etc.?

Do you extend the course of fidaxomicin past initial 10 days to at least 3-7 days after completion of antibiotics?

O'Toole et al., PMID 36652352

For example, do you routinely supplement with calcium carbonate, magnesium hydroxide, aluminum hydroxide, simethicone, sucralfate, etc.?

In other words, do you consider administering pre-operative IV fluids routinely or only under specific circumstances?

For example, do you consider "cautious" IV fluids or otherwise consider early vasopressors?

Assume QTc is not prolonged, electrolytes are reasonably normal, and the patient is not already on heavy psychotropic polypharmacy.

Do you use the traditional strict limit of 1.5 L, or do you consider removing more volume if a patient appears to tolerate it?

For example, would you consider alternatives to paracentesis (Denver shunt placement, CART therapy, or permanent tunneled catheters) that might better...

For example, do you find trending WBC, procalcitonin, CRP, etc., more or less helpful?

For example, do you think the benefits of sequential compression devices outweigh the risk of falls, delirium, etc.?

In particular, how do you reconcile situations where lung POCUS findings contradict other components of volume assessment (e.g. JVD, peripheral edema,...